Search

Your search keyword '"Vogelmeier, C.F."' showing total 38 results

Search Constraints

Start Over You searched for: Author "Vogelmeier, C.F." Remove constraint Author: "Vogelmeier, C.F."
38 results on '"Vogelmeier, C.F."'

Search Results

1. Alpha1-antitrypsin deficiency in Greece: Focus on rare variants

2. Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial

3. Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial

4. Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels <20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: From Phase 3 Boreas

5. Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial

6. In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

7. Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial

8. In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation

9. Impaired Left Ventricular Filling and All-cause Mortality in COPD

10. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort

11. RWD25 Healthcare Resource Utilization and Costs in Patients Experiencing Severe Cardiac Events Following a COPD Exacerbation: Results from EXACOS-CV Studies in Spain, Germany, the Netherlands and Canada

12. Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With COPD

15. Alpha1-antitrypsin deficiency in Greece: Focus on rare variants

16. Α1-ANTITRYPSIN DEFICIENCY IN GREEKS: FOCUS ON RARE VARIANTS

17. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis

18. mHealth Telemonitoring of Long COVID-19: A Mixed Methods Study on Challenges, Technology Acceptance and Perceived Added value

19. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations

20. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET

24. Improving lung health in low-income and middle-income countries: from challenges to solutions

25. PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model

29. Machine Learning Model for Asthma/COPD Differentiation Classification (ACDC) Outperforms Clinicians in a Retrospective Multiple-Rater Multiple-Case Review Study

30. Asthma/COPD Differentiation Classification (AC/DC): Machine Learning to Aid Physicians in Diagnosing Asthma, COPD and Asthma-COPD Overlap (ACO)

Catalog

Books, media, physical & digital resources